Key Takeaways
- Diabetes delivers the promised acceleration: The franchise grew closer to 14% in Q2 (17% H1), driven by execution discipline, public-sector expansion, and the innovative Toujeo/Soliqua portfolio, putting the full-year acceleration thesis firmly on track.
- Partnership business is the drag: The CV/CNS portfolio distributed by Cipla and Emcure grew only 2% in Q2, well below market, and management does not expect it to reach industry growth in 2026.
- H1 PBT masks underlying strength: Reported H1 PBT fell 4%, but stripping out the Q1 FY25 one-off partner inventory build and transition-related sales returns, management says both top line and PBT show high-digit growth.
- Cash pile grows, capital return stays cautious: Cash is up 34%, but a buyback is "not in the strategy" and the dividend expectation is minimum at last year's level, leaving the deployment path open-ended.
- What to watch next quarter: Whether the partnership reorganization by Cipla/Emcure translates into growth closer to market rates, the sustainability of the diabetes run-rate, and any early signal on Awiqli's impact on insulin initiation.
Diabetes Franchise: The Growth Engine
- Q2 performance: The diabetes business grew closer to 14%, powered by Toujeo and Soliqua, with close to 70% growth attributed to execution discipline, public-sector expansion, and acceleration in new state accounts.
- Market leadership cemented: Combined basal analog market share (Lantus + Toujeo) reached 58% by value and close to 61% by volume, with Toujeo alone growing by 11% in market share in value.
- Soliqua defies GLP-1 erosion: Soliqua grew 16% quarter-on-quarter despite GLP-1 market share gains, benefiting from increased share of voice and use in patients who cannot tolerate GLP-1 but need progressive insulin therapy without weight gain.
- Real-world evidence build: Four real-world experience publications between Q4 FY26 and Q2 FY27 are strengthening Toujeo and Soliqua positioning in Indian guidelines and KOL advocacy.
- Public sector as a growth pathway: 70% growth in the public sector came from expanding into new accounts of care, a lever management sees as a continuous pathway for the diabetes franchise.
- Insulin market dynamics: Overall insulin market growth may be slightly declining at initiation due to GLP-1 taking share, but the analog segment is sustaining double-digit growth irrespective of GLP-1, and higher single-digit overall insulin growth is expected to continue.
Deepak Arora: "I am very, very excited and delighted to share the domestic results of quarter 2 of 2026... As promised last time, we will be investing ourselves into making sure that we optimize and maximize diabetes business unit, growing by double-digit and bring it above market growth. And here we are."
Partnership Business: Below Expectations, Reorganization Underway
- Q2 growth of only 2%: The CV/CNS portfolio distributed by Cipla and Emcure grew just 2% year-on-year, which management attributed to aggressive market competition in the generic portfolio.
- H1 distorted by one-offs: H1 performance was impacted because Q1 FY25 included positive one-offs: safety stock supplied to partners during transition and favorable sales-return agreements, both absent in Q1 FY26.
- Partner reorganization: Both Cipla and Emcure have reorganized their teams to increase focus on the Sanofi portfolio, with Emcure creating a standalone team for Amaryl and the CV portfolio, separate from their other products.
- OAD via Emcure: The oral anti-diabetic segment distributed through Emcure is seeing sales-out that meets market growth, described as a promising direction.
- FY26 growth expectation reset: Management does not expect the partnership business to reach industry growth in 2026; 2027 is being evaluated for reaching that benchmark.
- No sidelining risk: Management explicitly denied analyst concerns that partners might push their own products over Sanofi's, stating "that could not be a situation" and there is "no such risk in this partnership."
Deepak Arora: "as we move couple of quarters, we should be getting closer to the market growth if not on the market growth, knowing that this is generic market, everyone is playing very competitive"
Financials: Underlying Strength Beneath the One-Off Noise
- Q2 total income: Up 7%, with sales (domestic + export) growing 6% and other operating income from services to Group entities and consumer health contributing the balance.
- Q2 domestic vs export: Domestic sales grew 8%, while exports declined 2%, weighed by heavy competition in the Australia market for mature products.
- Q2 PBT surge: Profit before tax grew 19% YoY from INR 94 crores to INR 112 crores, with PBT margin expanding from 24% to 27% of net sales.
- H1 PBT decline explained: The reported 4% H1 PBT decline is entirely attributable to the Q1 FY25 one-off partner inventory build and transition-period sales returns. Excluding all one-offs, management states both top line and PBT would show positive and high-digit growth respectively.
- Opex discipline: Operating expenses fell 5% in Q2 and 15% in H1, focused on personnel and other opex without impacting ROI-generating projects, a trend management says will continue without hurting the top line.
- Cash position: Cash grew 34%, described as very healthy with no major risk.
Rachid Ayari: "...yesterday we were in the Board Meeting, and we try to eliminate all one-off, and you find out that, you know, if you take all the one-off, you know, the top line will be positive. And if you take the bottom line, you know, the profit before tax and exceptional items, we have a kind of, you know, high-digit growth if we exclude, all the one-off from last year and all what is related to this transition period with the partners."
Export Business: Australia Headwinds, Goa Specialization Offsets
- Australia pressure: The export decline is driven by heavy competition in Australia for mature products, but the strategy of specializing the Goa site in certain products for worldwide supply is offsetting a significant part of the loss.
- Geographic diversification: Losses in Australia are being compensated by other markets including France, Italy, Turkey, and Russia, and the company is awaiting South Africa tender results.
- Goa site strategy: One product has already succeeded in making Goa a specialized manufacturing site for worldwide supply, and the company is awaiting South Africa tender results.
- CMO insourcing: Management is trying to bring back products currently outsourced to contract manufacturers to increase site volume and improve the export mix.
Competitive Landscape & Innovation Pipeline
- Awiqli (once-weekly insulin) threat: Management says it is too early to comment on major impact, but expects the market will open up for patients reluctant to initiate daily injections; the real momentum will only be visible after a quarter.
- GLP-1 as complement, not substitute: Toujeo and Lantus are used as complementary therapy with GLP-1s, and the increased GLP-1 share of voice is actually benefiting the insulin portfolio by raising overall awareness.
- Pipeline evaluation underway: The company is evaluating the diabetes pipeline from the parent, working on business cases for innovative devices, Bluetooth-enabled devices, and AI platforms to complement the insulin portfolio, though no specific timelines were given.
- AI and device initiatives: Management is preparing to simplify insulin initiation-to-intensification by bringing novel devices and AI platforms to strengthen the patient support program.
Deepak Arora: "I think it's too early to comment on if there's a major impact which will happen, but I think the market will open up, especially on the patients at the time of initiations, which were not getting onto the insulin therapy because of the daily injection"
Capital Allocation: Cash-Rich, Return-Cautious
- Dividend floor, not a target: Management expects the dividend to be at minimum last year's payout and "will not be lower than what we were doing in the past," but the final decision rests with the Board and no forward-looking commitment on payout ratio was given.
- Buyback off the table: When asked about using cash for an open market buyback, management stated "as today, it's not in the strategy" without elaboration.
- Cash deployment open question: With cash up 34%, no buyback, and dividend only committed at a floor, the deployment path for the growing cash pile remains undefined.
Rachid Ayari: "we are expecting that we will be minimum at last year payout, but then there are decisions and discussion that will be done at the Board and the final decision and the proposal will be from the Board. So, today, we cannot commit."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Diabetes franchise growth | Continue double-digit growth above market; "not leaving any grounds to make sure that what we have seen in the first half to repeat it in second half" | H2 FY27 |
| Partnership business growth | Not expected to reach industry growth in FY26; FY27 being evaluated for reaching industry growth | FY26 / FY27 |
| Partnership trajectory | "As we move couple of quarters, we should be getting closer to the market growth if not on the market growth" | Next few quarters |
| Opex trend | Opex reduction to continue without impacting top line | Ongoing |
| Dividend payout | Minimum at last year's payout level; final decision by Board | FY26 |
| Buyback | "As today, it's not in the strategy" | No timeline |
| Awiqli impact assessment | "We have to wait for a quarter to really see the momentum" | Q3 FY26 |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue (total income) | +7% YoY |
| Domestic sales growth | +8% YoY |
| Export sales growth | -2% YoY |
| Diabetes business growth | ~14% YoY |
| Diabetes business H1 growth | +17% |
| Partnership business growth | +2% YoY |
| Profit before tax and exceptional items | ₹112 cr, +19% YoY from ₹94 cr |
| PBT as percentage of net sales | 27%, up from 24% YoY |
| Operating expenses | -5% YoY |
| Cash position growth | +34% |
| Basal analog market share (value) | 58% |
| Basal analog market share (volume) | ~61% |
| Soliqua growth | +16% QoQ |
| Toujeo market share growth (value) | +11% |
| Public sector growth (Toujeo and Soliqua) | ~70% |